Abstract
Keywords
Permeation enhancers Permeation mechanism Transdermal delivery Huperzine A Microemulsion
Introduction
Huperzine A, a natural alkaloid derived from the Chinese herb Huperzia serrata, has been used for improving memory, cognitive and behavioral dysfunction in patients with Alzheimer’s disease (AD) in China, and is marketed in the United States as a dietary supplement (1). It is a selective, potent, and reversible inhibitor of acetylcholine esterase (AChE) with potency comparable to donepezil, galantamine and rivastigmine - drugs commonly prescribed for the treatment of AD (2). Currently, the main marketed pharmaceutical forms of huperzine A are oral immediate-release tablets and capsules, which have to be administrated at least twice a day. However, it is rather hard for AD patients with decreased memory to persist in taking medicines (3). Moreover, huperzine A exhibits a short elimination half-life of 4.81 h in human (4), which needs to be administered frequently, resulting in variable absorption profiles and cumulative toxicosis, leading to the reduction of compliance in AD patients.
Due to the undesirable side effects and non-compliance of the oral drug administration, transdermal drug delivery system (TDDS) appears to be an attractive alternative to the oral route, being beneficial in reducing the dosage interval, maintaining the relatively stable plasma drug concentration and improving the patients’ compliance (5). During the recent years, microemulsions have received increasing attention because of the advantages such as enhanced drug solubility, good thermodynamic stability, and improved delivery properties (6-8). In these regards, the TDDS using microemulsion as a vehicle is of particular clinical significance for the long-term treatment of a chronic disease like AD.
However, the stratum corneum (SC), the outermost layer of the skin, is the principal permeability barrier and rate-limiting step for transdermal delivery of drugs across the skin. SC is composed of keratin-enriched cells embedded in a multiple lipid bilayer, which mainly consists of ceramides, cholesterol and free fatty acids (9). It is widely accepted that keratin represents the hydrophilic barrier, whereas the intercellular lipids represent the hydrophobic barrier (10). A popular technique to overcome the permeability barrier involves the use of penetration enhancers, which promotes the transdermal delivery of drugs by disturbing the organization of the multiple lipid bilayers and increasing the skin diffusivity of drugs (11). Terpenes derived from plant essential oil have been widely used in the transdermal preparations as penetration enhancers (10, 12). They are considered as less toxic compounds with low irritancy compared with the synthetic penetration enhancers, such as solvents, surfactants, azones and pyrrolidones (13). Since single enhancer usually offers limited enhancement of skin permeability, more attentions have been paid on the combination of two or more enhancers for drug delivery to overcome the limitations of individual enhancers (14).
There are very few literatures relating to screening a suitable enhancer combination for the transdermal delivery of huperzine A and investigating the potential mechanisms of the synergy between the enhancers. The purpose of this study was therefore to investigate the influence and the mechanisms of cineole and terpineol on the in-vitro transdermal delivery of huperzine A from microemulsions, and their potential synergistic effect on permeation enhancement. The transdermal delivery of huperzine A from microemulsions with different concentrations of enhancers was evaluated in Franz-type diffusion cells through the rat abdominal skin. The partition coefficient of huperzine A between the full thickness skin and microemulsion was determined, and the effects of enhancers on SC as well as the potential mechanisms of permeation enhancement were further investigated with attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR).
Experimental
Materials and animals
Huperzine A (purity > 97.0%) was supplied by Wanbang Pharmaceutical Company (Zhejiang, China). Cremophor RH40 (RH40) was provided by BASF (Germany). Cineole (98%) and terpineol (98%) were obtained from Alfa Aesar (the United States). Trypsin was purchased from Sigma (the United States). All the other reagents were of analytical grade.
Male Sprague-Dawley rats (SPF grade), weighing 160-180 g, were supplied by the Experimental Animal Division of Peking University Health Sciences Center (Beijing, China). The studies were approved by the Institutional Animal Care and Use Committee of Tsinghua University (Beijing, China).
Preparation of microemulsions
Microemulsions were prepared using the water titration method (14). Briefly, 9 mg huperzine A was added to the mixtures of 1% oleic acid (as oil), 12% Cremophor RH40 (as surfactant), 4% ethanol (as cosurfactant) and different concentrations of enhancers (0.5%, 1%, 2%, and 3% of cineole or terpineol, and 0.5% cineole + 0.5% terpineol), and an appropriate amount of water was then added to the mixtures drop by drop. Various microemulsions were obtained by stirring the mixtures at ambient temperature. The microemulsions without enhancers were prepared as the control.
Microemulsion evaluation
The macroscopic phase behavior of vehicles was observed by polarized light microscope (Axiostar, Carl Zeiss Instruments, Germany). This polarized light screening technique was used extensively to provide information about the isotropy, anisotropy, and scattering of vehicles, through observing whether the sample rotates the plane of polarization of polarized light. The liquid-crystalline phase was easily distinguished by the birefringence displayed with polarized light.
The microstructure of the drug-loaded microemulsion was observed using freeze-fracture transmission electron microscopy (FF-TEM). Fracturing and replication were carried out in a high vacuum freeze etching system (Balzers BAF-400D, Balzers Instruments, Liechtenstein). The fracture surface was replicated by shadowing with Pt-C. The metal replicas were viewed under TEM (JEM-1200EX, JEOL Instruments, Japan).
The average droplet size and polydispersity index of the microemulsions were determined by laser scattering (Zetasizer 3000 HS, Malvern Instruments, UK).
Preparation of full thickness skin and stratum corneum
For in-vitro permeation studies, the rats were deeply anesthetized and sacrificed with an overdose of sodium pentobarbital (100 mg/Kg, IP). The abdominal skins were obtained after the hair was removed with an electric clipper. The adhering fat and connective tissue were removed carefully. The obtained full thickness skins were washed with physiologic saline, examined for integrity, and then placed in a refrigerator at - 80ºC until use.
For ATR-FTIR studies, the stratum corneum (SC) was separated from full thickness skin by digesting the skin in 10 mM phosphate-buffered saline (pH = 7.4) containing 0.1% (w/w) trypsin at 37ºC for 24 h (16). The isolated SC was rinsed with distilled water for three times, dried under a nitrogen stream, and stored in a desiccator over silica gel.
In-vitro skin permeation studies
The in-vitro penetration studies were performed in Franz-type diffusion cells (TPY-2 diffusion test apparatus, Shanghai Huanghai Drug Control Instrument Co. Ltd., Shanghai, China) with an effective diffusion area of 2.32 cm2 and a receptor volume of 6.5 mL. Ten mmol/L phosphate-buffered solution (PBS, pH = 7.4) was used as the receptor medium, which was magnetically stirred at 37 ± 0.5ºC with a constant rate of 600 rpm during the experiment. The microemulsions (2.0 g) were placed in the donor compartment. At predetermined times (2, 4, 6, 9 and 12 h), 200 μL of the receptor medium was withdrawn and replaced with an equal volume of freshly prepared medium. The samples were centrifuged for 15 min at 13000 rpm and an aliquot (10 μL) of the supernatant was analyzed by HPLC to determine the drug content. The experiment was replicated in triplicate.
The cumulative amount (Q, μg/cm2) of huperzine A from microemulsions permeated through the rat abdominal skin was plotted as a function of time and the slope of linear portion was estimated as steady-state permeation rate (Js, μg·cm-2·h-1).
Chromatography
Huperzine A was analyzed by reversed phase HPLC using Hitachi’s model L-2300 HPLC system (Tokyo, Japan), which consisted of a quaternary pump (L-2130, Hitachi, Japan), a UV detector (L-2400, Hitachi, Japan), an automatic injector (L-2200, Hitachi, Japan) and a workstation. The detection wavelength was set at 308 nm. The samples were injected directly into an Agilent TC-C18 column (4.6 mm × 250 mm, 5 μm) and eluted in a binary mixture of acetonitrile and 0.01% triethylamine solution (22:78, v/v) at a flow rate of 1.0 mL/min. The injection volume was 10 μL.
Method validation
The method was validated for linearity, accuracy, precision and selectivity according to the accepted guidelines of FDA (2001) for validation of bioanalytical methods (17).
The quantification of huperzine A was performed using standard calibration curve, which was generated by spiking the blank samples of skin extracts in receptor compartment with huperzine A to produce 6 concentration levels ranging between 0.2 and 200.0 μg/mL. The calibration curve was constructed by plotting the peak areas against concentration and analyzed by linear regression analysis.
Accuracy and precision evaluations were performed on both intra-day and inter-day measurements. Intra-day variability of the assay method was determined by repeated analysis of three concentrations of huperzine A (0.2, 100 and 200.0 μg/mL) in the same day. Similarly, inter-day variability was determined by repeated analysis of the same samples in three different days.
Sensitivity of the method was determined by calculating the limit of detection (LOD) and the lower limit of quantification (LLOQ). The LOD was defined as the lowest concentration of the analyte resulting in a signal-to-noise ratio of 3:1. The LLOQ was defined as the lowest drug concentration that could be determined quantitatively with appropriate precision and accuracy.
The selectivity for assessing potential interferences was tested by analyzing 6 blank samples of skin extracts in receptor compartment according to the procedure described above.
Partition coefficient measurement
The partition coefficient of huperzine A between the full thickness skins and microemulsions with different concentrations of enhancers (1.0% cineole, 1.0% terpineol, and 0.5% cineole + 0.5% terpineol, respectively) or without enhancers (as the control) was determined by placing each full thickness skin (100 mg) in vial containing 10 mL of microemulsion. After the vial was gently rotated at 37ºC for 24 h, an aliquot of 1.0 mL 10% (v/v) Triton X-100 in ethanol for emulsion breaking was added to 0.5 mL microemulsion, and the mixture was diluted suitably with acetonitrile-water (22:78, v/v). Thereafter, the concentration of huperzine A was assayed by HPLC.
ATR-FTIR studies
To investigate the skin modification induced by the enhancers and the potential synergistic interactions between cineole and terpineol, several pieces of SC were incubated in 2 mL of different solutions (1.0% cineole, 1.0% terpineol, and 0.5% cineole + 0.5% terpineol, respectively) at 4ºC for 12 h, and 40% ethanol (v/v) was used as the solvent for these enhancers as well as the negative control. Thereafter each SC was washed carefully with distilled water and desiccated under a nitrogen stream. Fourier transform infrared spectroscopic measurements were performed using a Perkin Elmer GX FTIR spectrometer equipped with a deuterated triglycine sulfate (DTGS) detector. All spectra were obtained as an average of 16 scans recorded between 4000 cm-1 and 400 cm-1 at 30ºC, with a spectral resolution of 2 cm-1 and a zero filling factor of 2. The frequency precise was better than 0.1 cm-1.
Statistical analysis
The transdermal penetration of huperzine A and FTIR spectra were measured using at least three skin or SC specimens, and all the data were expressed as the mean ± standard deviations (SD). A paired Student’s t-test (two-tailed) was performed when comparing two different conditions. In all cases, p < 0.05 was considered as significant.
Results and Discussion
Microemulsion evaluation
Microstructure of the drug-loaded microemulsion was characterized using FF-TEM (Figure 1). The average size of all microemulsions ranged from 14.3 ± 1.2 to 73.1 ± 5.9 nm, and the polydispersity index, ranging from 0.153 ± 0.002 to 0.186 ± 0.003, showed that all microemulsions had narrow size distribution.
Method validation
No interference of any peak was observed at the retention time for huperzine A (9.1 min), demonstrating a good selectivity of the assay method. The calibration plot was linear for huperzine A over the concentration range of 0.2-200.0 μg/mL, with the correlation coefficient of the standard curve being 0.999. The LOD and LLOQ of the method were 0.1 μg/mL and 0.2 μg/mL with the corresponding relative standard deviation (RSD) of 13.8% and 10.6%, respectively. The intra-day and inter-day accuracy and precision were lower than 10% RSD in all the concentrations analyzed, which satisfactorily met the international established acceptance criteria (17).
In-vitro skin permeation studies
Different concentrations of cineole and terpineol as enhancers were added to the microemulsions, respectively, to improve the permeation rate of huperzine A. The plot of the permeation rate of huperzine A against the concentration of enhancers is exhibited in Figure 2.
The permeation rate of huperzine A increased linearly with the concentration of the enhancers from 0% to 1%. Furthermore, when the amount of huperzine A in the microemulsions was kept constant and the concentration of the enhancers was varied, the maximal permeation rate was observed already at 1% cineole or 1% terpineol present in the microemulsions. Compared with the control microemulsions, the permeation rates of huperzine A from microemulsions with 1% cineole and 1% terpineol were significantly increased, being 4.58 and 16.64 times higher, respectively. The decreased permeation rate of huperzine A with the increasing concentration of cineole or terpineol might be attributed to the permeation obstruction caused by the higher viscosity of microemulsions with higher concentration of enhancer.
One of the predominant factors known to determine the permeation of drugs across skin is the partition coefficient (18). The huperzine A amounts partitioned between full thickness skins and microemulsions with 1% cineole and 1% terpineol were 7.29 ± 0.51 μg/g and 14.66 ± 1.18 μg/g, respectively, being significant higher than the huperzine A amount partitioned between thickness skin and the control microemulsion (3.16 ± 0.12 μg/g). Considering the structures (Figure 3), both of cineole and terpineol belong to oxygen-containing terpenes (11), which makes them easier to form hydrogen bond with ceramide head groups, and loose or even disrupt the existing hydrogen bond network at the head of ceramides in the SC lipid bilayers, thereby facilitating the permeation of huperzine A. The huperzine A amount partitioned between full thickness skin and microemulsion with 1% terpineol was much higher than that partitioned between full thickness skin and microemulsion with 1% cineole, whereas 1% cineole was more efficient in enhancing the permeability of huperzine A from microemulsion than 1% terpineol, which suggested that other mechanisms were probably responsible for the lower enhancement effect of terpineol compared with cineole.
Another predominant factor related to the permeation of drugs across skin is the diffusion coefficient. Diffusion is a size-dependent process and an increase in the diffusant volume as a result of molecular association, such as hydrogen bonding, will reduce diffusion coefficient (19). Huperzine A can accept and donate hydrogen bonds at more than one site (Figure 3). Terpineol, with the hydroxyl functionalities, can also accept or donate hydrogen bonds, whereas cineole, with the epoxy functionalities, can only accept hydrogen bonds (20). Therefore, the lower enhancement effect of terpineol in comparison with that of cineole could be partly attributed to the larger size of huperzine A-terpineol complex than that of huperzine A-cineole complex, possibly due to the differences in the stoichiometry of the interactions.
Additionally, the physicochemical characteristics such as log P and boiling point of terpene also play an important role in enhancing the permeabilities of several drugs (21). Since the log p-values of cineole (log P 2.82) and terpineol (log P 2.69) do not significantly differ from each other, the permeation enhancement cannot be attributed to their lipophilicity (21). On the other hand, the boiling point of cineole (173ºC) is approximately 44 ºC less than that of terpineol (217ºC), indicating that the cohesiveness or self-association of cineole is weaker than terpineol (21), which can be one of the reasons for cineole being more efficient in enhancing the permeability of huperzine A from microemulsions than terpineol.
Furthermore, the effects of 0.5% cineole + 0.5% terpineol on the transdermal delivery of huperzine A from microemulsions were investigated. A steady increase of huperzine A in the receptor compartment with time was observed and the permeation profiles followed zero-order release kinetics (Figure4A). Moreover, the permeation rate of huperzine A from microemulsion with 0.5% cineole + 0.5% terpineol was 20.48 times higher than that of the control microemulsion, and the enhancement of the permeation rate was significantly greater than the increase caused by 1% individual enhancers (Figure 4B). These results suggested that there were potential synergistic interactions between 0.5% cineole and 0.5% terpineol in transdermal delivery of huperzine A. In addition, the huperzine A amount partitioned between full thickness skin and microemulsion with 0.5% cineole + 0.5% terpineol was 16.80 μg/g, being significant higher than that partitioned between thickness skin and microemulsion with 1% cineole (7.29 μg/g) or 1% terpineol (14.66 μg/g), which suggested that 0.5% cineole + 0.5% terpineol could influence the partition coefficient with synergic effect. Taking these aspects together, 0.5% cineole and 0.5% terpineol might compensate each other with different mechanisms, such as influencing the partition and diffusion coefficients of the drug, in enhancing the permeability of huperzine A from microemulsions. Therefore, 0.5% cineole + 0.5% terpineol as the enhancer combination might be suitable for future studies due to its higher permeation enhancing effect.
ATR-FTIR studies
ATR-FTIR as a powerful tool for determining the fluidity of SC and the structural alteration of lipids and keratin in SC has been extensively used to investigate the effects of penetration enhancers on SC (16, 23). The ATR-FTIR spectra of rat SC treated with various enhancers are displayed in Figure 5. Characteristic peaks could be found in CH2 asymmetric stretching vibration [νa (CH2)] frequency peak near 2920 cm-1, CH2 symmetric stretching vibration [νs (CH2) ] frequency peak near 2850 cm-1, and C=O stretching vibration [ν (CO) ] frequency peak near 1650 cm-1 (16). The CH2 stretching vibration frequencies were derived from methylene group on the hydrophobic alkyl chains of intercellular lipids (ceramides, cholesterol and fatty acids) in SC, being significantly influenced by the incorporation of enhancers (23). The C=O stretching vibration frequency was derived from carbonyl group from the amide ׀ of the keratin in SC (16).
As showed in Figure 5 and Table 1, SC exposed to 40% ethanol in the absence of enhancers (the negative control) exhibited νa (CH2), νs (CH2), and ν (CO) peaks at 2917.1, 2849.3, and 1644.0 cm-1, respectively. SC treated with 1% cineole alone and 1% terpineol alone caused blue shifts in νa (CH2) of 1.2 cm-1 and 0.9 cm-1 relative to the negative control, respectively. Interestingly, SC treated with 0.5% cineole + 0.5% terpineol caused a blue shift in νa (CH2) of 2.1 cm-1 relative to the negative control, which was significantly different from SC treated with 1% individual enhancers.
Effect of various enhancers on the νa (CH2), νs (CH2) and ν (CO) stretching vibration shifts (cm-1).
| Treatment | νa (CH2) | νs (CH2) | ν(CO) |
|---|---|---|---|
| 1% Cineole | 2918.3 ± 0.2 a, b | 2849.9 ± 0.2 a | 1643.4 ± 0.3 a, b |
| 1% Terpineol | 2918.0 ± 0.1 a, b | 2849.6 ± 0.2 a, b | 1643.8 ± 0.1a, b |
| 0.5% Cineole + 0.5% Terpineol | 2919.2 ± 0.1 a | 2850.4 ± 0.2 a | 1640.9 ± 0.2 a |
| Negative control | 2917.1 ± 0.2 b | 2849.3 ± 0.2 b | 1644.0 ± 0.1 b |
Furthermore, SC treated with 1% cineole, 1% terpineol, and 0.5% cineole + 0.5% terpineol also produced blue shifts in νs (CH2) peak position, and the peak shifts by these enhancers were 0.6 cm-1, 0.3 cm-1 and 1.1 cm-1 relative to the negative control, respectively. Altogether, the significant blue shifts in both νa (CH2) and νs (CH2) of lipid alkyl chains in SC indicated that both of 1% cineole and 1% terpineol could increase the disorderliness and fluidity of SC lipid alkyl chains to some extent, and this disorder could be further increased when SC was treated with 0.5% cineole + 0.5% terpineol.
Additionally, SC treated with 1% cineole alone and 1% terpineol alone caused decreases in ν (CO) of 0.6 cm-1 and 0.2 cm-1 relative to the negative control, respectively, which suggested that the keratin in SC was also affected by 1% cineole and 1% terpineol. Furthermore, SC treated with 0.5% cineole + 0.5% terpineol caused a significant decrease in ν (CO) of 3.1 cm-1 relative to the negative control, and the decrease was significantly different from SC treated with 1% individual enhancers. The abovementioned data indicated that both 1% cineole and 1% terpineol could change the structure of keratin in SC through promoting a transformation from α-helix to random coiling structure of the keratin and loosing the accumulative structure of keratin, eventually enhancing the transdermal permeabilities of drugs (25). Most importantly, 0.5% cineole and 0.5% terpineol could act synergistically to transform the structure of keratin.
Furthermore, ATR-FTIR results in Table 2 showed that cineole and terpineol could also cause significant lipid extraction to different extents indicated by the remarkable decreases in the peak areas of νa (CH2) (the baseline was set at 2998.0-2860.0 cm-1) and νs (CH2) (the baseline was set at 2860.0-2840.0 cm-1) by 69.92% and 68.74%, 17.71% and 15.42%, 14.83% and 19.67% corresponding to 0.5% terpineol + 0.5% cineole, 1% cineole, and 1% terpineol compared with the negative control, respectively. The decreasing trend in peak areas was 0.5% terpineol + 0.5% cineole > 1% cineole > 1% terpineol. The peak areas were most significantly diminished when 0.5% cineole + 0.5% terpineol was adopted, indicating that there were synergistic interactions between cineole and terpineol to extract SC lipids.
Effect of various enhancers on the νa (CH2), νs (CH2) and ν (CO) peak areas
| Treatment | νa (CH2) | νs (CH2) | ν(CO) |
|---|---|---|---|
| 1% Cineole | 10.45 ± 0.47 a,b | 1.43 ± 0.08 a, b | 16.88 ± 0.83 a, b |
| 1% Terpineol | 10.82 ± 0.52 a, b | 1.36 ± 0.06 a, b | 20.82 ± 1.56 a, b |
| 0.5% Cineole + 0.5% Terpineol | 3.82 ± 0.12 a | 0.53 ± 0.03 a | 8.36 ± 0.38 a |
| Negative control | 12.70 ± 0.66 b | 1.70 ± 0.09 b | 21.63 ± 1.62 b |
These results above could explain that both of cineole and terpineol possessed enhanced effects on the in-vitro transdermal delivery of huperzine A from microemulsions, and further proved that 0.5% cineole and 0.5% terpineol could act synergistically to improve the permeability of huperzine A.
Conclusion
The effects and enhanced mechanisms of cineole and terpineol as terpene enhancers on the in-vitro transdermal delivery of huperzine A from microemulsions were investigated. The results indicated that both cineole and terpineol could increase the transdermal delivery of huperzine A from microemulsions, and 0.5% cineole + 0.5% terpineol could influence the partition and diffusion coefficients of the drug through potential synergistic interactions between the two enhancers resulting in dramatically increasing the permeability of huperzine A. The ATR-FTIR spectroscopy investigation further authenticated the synergistic effect and revealed that the enhancing mechanisms were related to increasing the disorderliness and fluidity of SC lipid alkyl chains, disrupting the structure of keratin in SC, and extracting SC lipids. Generally speaking, 0.5% cineole + 0.5% terpineol might provide an alternative permeation enhancer combination for the transdermal delivery of huperzine A.
Acknowledgements
References
-
1.
Park P, Schachter S, Yaksh T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. Neurosci. Lett. 2010;470:6-9. [PubMed ID: 20026382].
-
2.
Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer›s disease. Neurosci. Lett. 2001;300:157-60. [PubMed ID: 11226635].
-
3.
Ye JC, Zeng S, Zheng GL, Chen GS. Pharmacokinetics of huperzine A after transdermal and oral administration in beagle dogs. Int. J. Pharm. 2008;356:187-92. [PubMed ID: 18289810].
-
4.
Qian BC, Wang M, Zhou ZF, Chen K, Zhou RR, Chen GS. Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol. Sin. 1995;16:396-8.
-
5.
Subedi RK, Oh SY, Chun MK, Choi HK. Recent advances in transdermal drug delivery. Arch. Pharm. Res. 2010;33:339-51. [PubMed ID: 20361297].
-
6.
Heuschkel S, Goebel A, Neubert RHH. Microemulsions-Modern Colloidal Carrier for Dermal and Transdermal Dru Delivery. J. Pharm. Sci. 2008;97:603-31. [PubMed ID: 17696162].
-
7.
Aboofazeli R, Mortazavi SA, Khoshnevis P. In-vitro Release Study of Sodium Salicylate from Lecithin Based Phospholipid Microemulsions. Iranian J. Pharm. Res. 2003;2:95-101.
-
8.
Cevc G, Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J. Control. Release. 2010;141:277-99. [PubMed ID: 19850095].
-
9.
Pilgram GS, Vanpelt AM, Spies F, Bouwstra JA, Koerten HK. Cryo-electron diffraction as a tool to study local variations in the lipid organization of human stratum corneum. J. Microsc. 1998;189:71-8. [PubMed ID: 9503659].
-
10.
Narishetty STK, Panchagnula R. Effect of L-menthol and 1, 8-cineole on phase behavior and molecular organization of SC lipids and skin permeation of zidovudine. J. Control. Release. 2005;102:59-70. [PubMed ID: 15653134].
-
11.
Williams AC, Barry BW. Penetration enhancers. Adv. Drug Deliv. Rev. 2004;56:603-18. [PubMed ID: 15019749].
-
12.
Singh G, Ghosh B, Kaushalkumar D, Somsekhar V. Screening of venlafaxine hydrochloride for transdermal delivery: passive diffusion and iontophoresis. AAPS Pharm. Sci. Tech. 2008;9:791-7.
-
13.
Sapra B, Jain S, Tiwary AK. Percutaneous permeation enhancement by terpenes: mechanistic view. AAPS J. 2008;10:120-31. [PubMed ID: 18446512].
-
14.
Karande P, Jain A, Mitragotri S. Insights into synergistic interactions in binary mixtures of chemical permeation enhancers for transdermal drug delivery. J. Control. Release. 2006;115:85-93. [PubMed ID: 16935378].
-
15.
Zhu W, Yu A, Wang W, Dong R, Wu J, Zhai G. Formulation design of microemulsion for dermal delivery of penciclovir. Int. J. Pharm. 2008;360:184-90. [PubMed ID: 18541394].
-
16.
Obata Y, Utsumi S, Watanabe H, Suda M, Tokudome Y, Otsuka M, Takayama K. Infrared spectroscopic study of lipid interaction in stratum corneum treated with transdermal absorption enhancers. Int. J. Pharm. 2010;389:18-23. [PubMed ID: 20079819].
-
17.
-
18.
Williams AC, Barry BW. Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement. Pharm. Res. 1991;8:17-24. [PubMed ID: 2014203].
-
19.
Moghimi HR, Williams AC, Barry BW. Enhancement by terpenes of 5-fluorouracil permeation through the stratum corneum: model solvent approach. J. Pharm. Pharmacol. 1998;50:955-64. [PubMed ID: 9811155].
-
20.
Jain AK, Thomas NS, Panchagnula R. Transdermal drug delivery of imipramine hydrochloride.: Effect of terpenes. J. Control. Release. 2002;79:93-101. [PubMed ID: 11853921].
-
21.
Narishetty STK, Panchagnula R. Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. J. Control. Release. 2004;95:367-79. [PubMed ID: 15023449].
-
22.
Drakulić BJ, Juranić IO, Erić S, Zloh M. Role of complexes formation between drugs and penetration enhancers in transdermal delivery. Int. J. Pharm. 2008;363:40-9. [PubMed ID: 18675333].
-
23.
Krishnaiah YSR, Al-Saidan SM, Chandrasekhar DV, Rama B. Effect of nerodilol and carvone on in-vitro permeation of nicorandil across rat epidermal membrane. Drug Dev. Ind. Pharm. 2006;32:423-35. [PubMed ID: 16638680].
-
24.
Kim YC, Late S, Banga AK, Ludovice PJ, Prausnitz MR. Biochemical enhancement of transdermal delivery with magainin peptide: Modification of electrostatic interactions by changing pH. Int. J. Pharm. 2008;362:20-8. [PubMed ID: 18601987].
-
25.
He W, Guo X, Xiao L, Feng M. Study on the mechanisms of chitosan and its derivatives used as transdermal penetration enhancers. Int. J. Pharm. 2009;382:234-43. [PubMed ID: 19686826].